Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

81.99 -0.47 (-0.57%)
Streaming Delayed Price Updated: 12:52 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101,405
Open 81.59
Bid (Size) 81.98 (200)
Ask (Size) 82.31 (300)
Prev. Close 82.46
Today's Range 81.59 - 83.39
52wk Range 33.70 - 96.54
Shares Outstanding 62,107,572
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-6.0%
-6.0%
1 Month
-1.7%
-1.7%
3 Month
-2.8%
-2.8%
6 Month
+45.8%
+45.8%
1 Year
+117.2%
+117.2%

More News

Read More
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗
Via Stocktwits
News headline image
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist (PTGX) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Via ACCESS Newswire
News headline image
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
Via ACCESS Newswire
News headline image
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
Via Benzinga
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Via ACCESS Newswire
News headline image
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
Via The Motley Fool
Topics Energy
News headline image
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
Via The Motley Fool
News headline image
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
News headline image
2 Top Dividend Kings Every Income Investor Should Own ↗
Via The Motley Fool
Topics Bonds
News headline image
Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗
Via MarketBeat
News headline image
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗
Via Benzinga
News headline image
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
Via Stocktwits
Topics Government World Trade
News headline image
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗
Via Benzinga
News headline image
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗
Via Benzinga
News headline image
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗
Via Chartmill
Topics Artificial Intelligence Government World Trade
News headline image
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗
Via The Motley Fool
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 81.99
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 02/18/26 12:52 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 5.09B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.